[an error occurred while processing this directive]
临床研究

维持性血液透析患者首次透析血清白蛋白水平与预后的相关性研究

  • 马荣 ,
  • 毛楠 ,
  • 肖祥 ,
  • 谢春鹏 ,
  • 奉娅
展开
  • 610500 成都,1成都市新都区人民医院内分泌肾脏科
    610500 成都,2成都医学院第一附属医院肾脏内科

收稿日期: 2024-04-02

  修回日期: 2024-12-03

  网络出版日期: 2025-02-12

基金资助

2022年成都医学院科技基金立项项目(CYZYB22-02)

Correlation between first dialysis serum albumin level and prognosis in maintenance hemodialysis patients

  • MA Rong ,
  • MAO Nan ,
  • XIAO Xiang ,
  • XIE Chun-Peng ,
  • FENG Ya
Expand
  • Department of Endocrinology and Nephrology, Xindu District People's Hospital, Chengdu 610500, China; 2Department of Nephrology, the First Affiliated Hospital of Chengdu Medical University, Chengdu 610500, China 

Received date: 2024-04-02

  Revised date: 2024-12-03

  Online published: 2025-02-12

摘要

目的  探讨维持性血液透析(maintenance hemodialysis,MHD)患者首次透析血清白蛋白(ALB)水平与预后的相关性。 方法  回顾性分析2009年1月─2022年10月成都医学院第一附属医院血液净化中心MHD患者,共纳入并评估了1000例,收集患者的人口统计学及临床特征资料,研究终点为全因死亡。采用R语言获得ALB最佳截点值,根据ALB截点值将患者分为高ALB组(n=808)和低ALB组(n=192),分析不同ALB水平患者的临床特征以及ALB与临床指标的相关性,评估ALB对MHD患者的预后影响。  结果  ALB与血红蛋白(r=0.176,P<0.001)、Kt/V(r=0.217,P<0.001)、URR(r=0.192,P<0.001)、血肌酐(r=0.259,P<0.001)、血钙(r=0.225,P<0.001)、血磷(r=0.225,P<0.001)、PTH(r=0.196,P<0.001)呈正相关关系,与年龄(r=-0.147,P=0.001)、C反应蛋白(r=-0.279,P<0.001)、葡萄糖(r=-0.145,P<0.001) 呈负相关关系。随访期间1000例MHD患者中164(16.40%)例发生死亡,除了年龄(HR=1.022,95% CI:1.010~1.034,P<0.001)、PTH(HR=0.999,95% CI:0.998~1.000,P=0.046)、尿素清除指数、尿素减少率以外,ALB水平是MHD患者死亡的独立预测因子(HR =0.940,95% CI:0.904~0.977,P=0.002)。 结论  首次透析低ALB水平是MHD患者预后不良的独立危险因素。首次透析ALB在39.8 g/L以上的MHD患者的预后更好。临床医生应该重视MHD患者的首次透析ALB水平,MHD患者首次透析ALB水平越高其全因死亡风险越低。

本文引用格式

马荣 , 毛楠 , 肖祥 , 谢春鹏 , 奉娅 . 维持性血液透析患者首次透析血清白蛋白水平与预后的相关性研究[J]. 中国血液净化, 2025 , 24(02) : 108 -112 . DOI: 10.3969/j.issn.1671-4091.2025.02.002

Abstract

Objective  This study aimed to explore the clinical characteristics of first dialysis serum albumin (ALB) level in patients with maintenance hemodialysis (MHD) and its influence on prognosis, and to analyze the value in predicting all-cause death in patients with MHD.  Methods  A retrospective analysis was performed in the Blood Purification Center from January 20009 to October 2022, and 1000 patients with MHD were finally included. The demographic and clinical characteristics of the patients were collected. The study endpoint was all-cause death. The optimal cut-off point of ALB is obtained by using R software. The patients were divided into groups (high ALB group and low ALB group) according to the ALB cut-off value. The clinical characteristics of patients with different ALB levels and the correlation between ALB and clinical indicators were analyzed, and the influence of ALB on the prognosis of MHD patients was evaluated. Results ALB and hemoglobin (r=0.176, P<0.001), Kt/V (r=0.217, P<0.001), URR (r=0.192, P<0.001), blood creatinine (r=0.259, P<0.001), blood calcium (r=0.225, P<0.001), blood phosphorus (r=0.225, P<0.001), PTH (r=0.196, P<0.001) are positively correlated, and negatively correlated with age (r=-0.147, P=0.001), C-reactive protein (r=-0.279, P<0.001), and glucose (r=-0.145, P<0.001). During the follow-up period, 164 patients (16.40%) died, age (HR=1.022, 95% CI: 1.010~1.034, P<0.001, PTH (HR=0.999, 95% CI: 0.998~1.000, P=0.046), urea clearance index, urea reduction rate, and ALB level is an independent predictor of mortality in MHD patients (HR=0.940, 95% CI: 0.904~0.977, P=0.002). Conclusion Low ALB level on first dialysis is an independent risk factor of all-cause death in MHD patients. MHD patients with ALB level above 39.8g/L on first dialysis have a better prognosis. Clinicians should pay attention to the ALB level of MHD patients on first dialysis. The higher the ALB level of MHD patients on first dialysis, the lower the risk of all-cause death.

参考文献

1. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012 Mar 3;379(9818):815-22.?
2. Yang F, Liao M, Wang P, Liu Y. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China. BMJ Open. 2021 Feb 5;11(2):e039653.
3. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009 Oct 28;302(16):1782-9.
4. Roberts MA, Polkinghorne KR, McDonald SP, Ierino FL. Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am J Kidney Dis. 2011 Jul;58(1):64-72.?
5. Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial. 2013 Jun;17(3):298-304.?
6. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O'Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015 Jul;66(1 Suppl 1):Svii, S1-305.?
7. Feingold E, Adams J, Penprase B, Tubie B. Effect of body mass index and albumin on mortality rates for adult African-American hemodialysis patients. J Am Assoc Nurse Pract. 2015 Nov;27(11):637-45.?
8. Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. Am J Med. 2017 Dec;130(12):1465.e11-1465.e19.
9. Okyay P. Comments on: The effect of an educational program on quality of life in patients undergoing hemodialysis in Western Saudi Arabia. Saudi Med J. 2019 Jun;40(6):628-629.
10 Antunes SA, Canziani ME, Campos AF, Vilela RQ. Hypoalbuminemia seems to be associated with a higher rate of hospitalization in hemodialysis patients. J Bras Nefrol. 2016 Mar;38(1):70-5.?
11. Reeves, P.B. and F.R. Mc Causland, Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension. Clin J Am Soc Nephrol, 2018. 13(8): p. 1297-1303.
12. Friedman, A.N. and S.Z. Fadem, Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol, 2010. 21(2): p. 223-30.
13. Carrero JJ, Aguilera A, Stenvinkel P, Gil F, Selgas R, Lindholm B. Appetite disorders in uremia. J Ren Nutr. 2008 Jan;18(1):107-13.
14. Sahathevan S, Khor BH, Ng HM, Gafor AHA, Mat Daud ZA, Mafra D, Karupaiah T. Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review. Nutrients. 2020 Oct 15;12(10):3147.
15. Zhang, W.J. and B. Frei, Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res, 2002. 55(4): p. 820-9.
16. Lim PS, Jeng Y, Wu MY, Pai MA, Wu TK, Liu CS, Chen CH, Kuo YC, Chien SW, Chen HP. Serum oxidized albumin and cardiovascular mortality in normoalbuminemic hemodialysis patients: a cohort study. PLoS One. 2013 Jul 29;8(7):e70822.?
17. Oettl, K. and R.E. Stauber, Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol, 2007. 151(5): p. 580-90.
18. Lim, P.S., Y.M. Cheng, and S.M. Yang, Impairments of the biological properties of serum albumin in patients on haemodialysis. Nephrology (Carlton), 2007. 12(1): p. 18-24.
19. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002 Nov;62(5):1524-38.
20. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK; HEMO Study Group. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis. 2002 Oct;40(4):721-7.?
21. Nagai K, Tsuchida K, Ishihara N, et al. Implications of Albumin Leakage for Survival in Maintenance Hemodialysis Patients: A 7-year Observational Study. Ther Apher Dial 2017;21:378-86.
22. Van Gelder MK, Abrahams AC, Joles JA, et al. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant 2018;33:906-13.
23. Forghani MS, Jadidoleslami MS, Naleini SN, Rajabnia M. Measurement of the serum levels of serum troponins I and T, albumin and C-Reactive protein in chronic hemodialysis patients and their relationship with left ventricular hypertrophy and heart failure. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):522-525.?
24. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CS, Camici PG. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol. 2008 Jan;3(1):19-26.
25. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009 May;4(5):914-20.?
26. Ishida I, Hirakata H, Sugimori H, Omae T, Hirakata E, Ibayashi S, Kubo M, Fujishima M. Hemodialysis causes severe orthostatic reduction in cerebral blood flow velocity in diabetic patients. Am J Kidney Dis. 1999 Dec;34(6):1096-104.?
27. Hryciw N, Joannidis M, Hiremath S, Callum J, Clark EG. Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy. Clin J Am Soc Nephrol. 2021 May 8;16(5):820-828.
文章导航

/

[an error occurred while processing this directive]